{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:47:36Z","timestamp":1788583656824,"version":"build-2803163510"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumor immune microenvironment (TIME) plays a key role to understand how tumors respond to prostate cancer (PC) therapies and potential mechanisms of resistance. Previous research has suggested that specific genomic aberrations, such as microsatellite instability (MSI) or CDK12 bi-allelic loss can allow PC patients more likely to respond to immune checkpoint inhibitors (ICI) or other immune therapies. However, responses to these treatments remain highly variable even in selected patients. Thus, it is essential to obtain more information about tumor immune cells that infiltrate these tumors, and on their plasticity and interactions, in order to better understand the underlying biology to allow development of new therapeutic strategies. This review analyzes: 1) How interactions among immune cell populations and other cells infiltrating the tumor stroma can modulate the progression of PC, 2) How the standard therapies to treat PC (such as androgen deprivation therapy, new androgen-directed hormone therapy or chemotherapy) may influence the dynamic changes of the immunome and 3) What are the limitations in characterizing the immune landscape of the host\u00b4s response to tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1398109","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:31:09Z","timestamp":1732084269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunome profiling in prostate cancer: a guide for clinicians"],"prefix":"10.3389","volume":"15","author":[{"given":"Luis","family":"San-Jose Manso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantzazu","family":"Alfranca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Moreno-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ruiz-Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Toquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Aldave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Celada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Dolores","family":"Fenor de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Romero-Laorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9550","DOI":"10.3390\/ijms22179550","article-title":"The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer","volume":"22","author":"Melo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-023-00407-0","article-title":"ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer","volume":"12","author":"Xin","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v120.21","article-title":"Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio","volume":"120","author":"Templeton","year":"2014","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","article-title":"Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses","volume":"14","author":"Hirz","year":"2023","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.celrep.2019.07.068","article-title":"Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer","volume":"28","author":"Di Mitri","year":"2019","journal-title":"Cell Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339911","article-title":"Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology","volume":"119","author":"Pello","year":"2012","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","article-title":"Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets","volume":"35","author":"Cassetta","year":"2019","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0992","article-title":"CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy","volume":"75","author":"Escamilla","year":"2015","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.10.001","article-title":"Taxane-induced attenuation of the CXCR2\/BCL-2 axis sensitizes prostate cancer to platinum-based treatment","volume":"79","author":"Ruiz de Porras","year":"2021","journal-title":"Eur Urol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.191","article-title":"Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression","volume":"33","author":"Comito","year":"2014","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imm.v168.2","article-title":"Cellular landscape of tumour microenvironment in prostate cancer","volume":"168","author":"Feng","year":"2023","journal-title":"Immunology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5354-5","article-title":"High absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy","volume":"23","author":"Shigeta","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13052","article-title":"Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer","volume":"8","author":"Hayashi","year":"2017","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-020-01373-2","article-title":"Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database","volume":"32","author":"Yirga","year":"2021","journal-title":"Cancer Causes Control CCC"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2017.05.013","article-title":"PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer","volume":"5","author":"Petitprez","year":"2019","journal-title":"Eur Urol. Focus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pros.v74.14","article-title":"Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer","volume":"74","author":"Ness","year":"2014","journal-title":"Prostate"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"119132","DOI":"10.1016\/j.lfs.2021.119132","article-title":"The role of regulatory T cells in the pathogenesis and treatment of prostate cancer","volume":"284","author":"Karpisheh","year":"2021","journal-title":"Life Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/pros.v79.14","article-title":"Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis","volume":"79","author":"Watanabe","year":"2019","journal-title":"Prostate"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i16","article-title":"Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer","volume":"6","author":"Pasero","year":"2015","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jim.2009.06.004","article-title":"Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients","volume":"348","author":"Gannon","year":"2009","journal-title":"J Immunol Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1965","article-title":"Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity","volume":"76","author":"Pasero","year":"2016","journal-title":"Cancer Res"},{"key":"B28","article-title":"Association between natural killer cell activity and prostate cancer: a pilot study","volume":"24","author":"Barkin","year":"2017","journal-title":"Can J Urol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586126","article-title":"Prostate cancer peripheral blood NK cells show enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 production and secrete monocyte-recruiting and polarizing factors","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00615-5","article-title":"Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis","volume":"26","author":"Bronte","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00090-14","article-title":"Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression","volume":"34","author":"Garcia","year":"2014","journal-title":"Mol Cell Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discovery"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3145","article-title":"TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients","volume":"21","author":"Hossain","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1078060","article-title":"Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer","volume":"5","author":"Pal","year":"2015","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00199","article-title":"Fate mapping of dendritic cells","volume":"6","author":"Poltorak","year":"2015","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"517493","DOI":"10.1155\/2010\/517493","article-title":"Dendritic cell-based immunotherapy for prostate cancer","volume":"2010","author":"J\u00e4hnisch","year":"2010","journal-title":"Clin Dev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23738","article-title":"Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer","volume":"79","author":"Krueger","year":"2019","journal-title":"Prostate"},{"key":"B42","article-title":"Serum interleukin 6 as a prognostic factor in patients with prostate cancer","volume":"6","author":"Nakashima","year":"2000","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1590\/s1807-59322011000700004","article-title":"Tgf-\u03b21 expression as a biomarker of poor prognosis in prostate cancer","volume":"66","author":"dos Reis","year":"2011","journal-title":"Clinics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.37349\/etat","article-title":"The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors","volume":"3","author":"Palano","year":"2022","journal-title":"Explor Targeting Anti-Tumor Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01051","article-title":"Expression of indoleamine 2,3-dioxygenase induced by IFN-\u03b3 and TNF-\u03b1 as potential biomarker of prostate cancer progression","volume":"9","author":"Banzola","year":"2018","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0282","article-title":"How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances","volume":"21","author":"Messerschmidt","year":"2016","journal-title":"Oncologist"},{"key":"B47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.humimm.2010.02.007","article-title":"Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses","volume":"71","author":"Morse","year":"2010","journal-title":"Hum Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251140998","article-title":"T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer","volume":"98","author":"Mercader","year":"2001","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0321","article-title":"Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer","volume":"17","author":"Saylor","year":"2012","journal-title":"Oncologist"},{"key":"B50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.21037\/atm-19-1913","article-title":"Levels of plasma cytokine in patients undergoing neoadjuvant androgen deprivation therapy and external beam radiation therapy for adenocarcinoma of the prostate","volume":"8","author":"Singh","year":"2020","journal-title":"Ann Transl Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.3390\/ijms20081831","article-title":"Reduced T-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients","volume":"20","author":"Pal","year":"2019","journal-title":"Novo Resistant to Abiraterone and\/or Enzalutamide Ther Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0371","article-title":"Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression","volume":"8","author":"Consiglio","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother. Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2703","article-title":"PD-L1 is highly expressed in Enzalutamide resistant prostate cancer","volume":"6","author":"Bishop","year":"2015","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"8580043","DOI":"10.1155\/2022\/8580043","article-title":"The roles of tumor-associated macrophages in prostate cancer","volume":"2022","author":"Han","year":"2022","journal-title":"J Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discovery"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0580","article-title":"High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot","volume":"8","author":"Keam","year":"2020","journal-title":"J Immunother. Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2741","article-title":"Activation of thymic regeneration in mice and humans following androgen blockade","volume":"175","author":"Sutherland","year":"2005","journal-title":"J Immunol Baltim. Md 1950"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6098","article-title":"Augmentation of T cell levels and responses induced by androgen deprivation","volume":"173","author":"Roden","year":"2004","journal-title":"J Immunol Baltim. Md 1950"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2499","article-title":"Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells","volume":"72","author":"Tang","year":"2012","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/biomedicines10030537","article-title":"Immunotherapy in advanced prostate cancer: current knowledge and future directions","volume":"10","author":"L\u00f3pez-Campos","year":"2022","journal-title":"Biomedicines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-4028","article-title":"Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer","volume":"81","author":"El-Kenawi","year":"2021","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","article-title":"Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"biomark Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1102","article-title":"589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)","volume":"32","author":"Navarro","year":"2021","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1260772","article-title":"Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel","volume":"56","author":"Buttigliero","year":"2017","journal-title":"Acta Oncol Stockh. Swed."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02265-4","article-title":"Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel","volume":"51","author":"Man","year":"2019","journal-title":"Int Urol. Nephrol."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23810","article-title":"Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling","volume":"79","author":"Xiang","year":"2019","journal-title":"Prostate"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.e16044","article-title":"Correlation of serum interleukin-6 (IL-6) levels and clinical outcome in hormone-independent (HI) prostate cancer (PC) patients (PTS) treated with docetaxel","volume":"27","author":"Visa","year":"2009","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","article-title":"Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer Oxf. Engl 1990"},{"key":"B71","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/genes12050773","article-title":"Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1\/CSF1R\u2013CXCL12\/CXCR4 Axis in Castration-Resistant Prostate Cancer","volume":"12","author":"Guan","year":"2021","journal-title":"Genes"},{"key":"B72","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/jcm8030354","article-title":"Suppressive role of androgen\/androgen receptor signaling via chemokines on prostate cancer cells","volume":"8","author":"Izumi","year":"2019","journal-title":"J Clin Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e2020838118","DOI":"10.1073\/pnas.2020838118","article-title":"Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells","volume":"118","author":"Pienta","year":"2021","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"B74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/tcr-22-2354","article-title":"The abscopal effect and its implications for radiotherapy-immunotherapy combinations","volume":"12","author":"Rowell","year":"2023","journal-title":"Transl Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","article-title":"Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors","volume":"14","author":"Rudqvist","year":"2023","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3946320231158025","DOI":"10.1177\/03946320231158025","article-title":"Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy","volume":"37","author":"Erlandsson","year":"2023","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12957-021-02325-z","article-title":"The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer","volume":"19","author":"He","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41467-021-27833-0","article-title":"Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3K\u03b1\/\u03b2\/\u03b4 treatment","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"NPJ Precis. Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2310","article-title":"LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study","volume":"35","author":"Agarwal","year":"2024","journal-title":"Ann Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"17562872231182219","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1601","article-title":"Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1231315","article-title":"Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer","volume":"14","author":"Esparcia-Pinedo","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","article-title":"Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv Sci Weinh. Baden-Wurtt. Ger."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4289","article-title":"Therapeutic implications for intrinsic phenotype classification of metastatic castration-resistant prostate cancer","volume":"28","author":"Coleman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v129.14","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70372-8","article-title":"Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study","volume":"13","author":"Olmos","year":"2012","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0327-7_17","article-title":"EPIC: A tool to estimate the proportions of different cell types from bulk gene expression data","volume":"2120","author":"Racle","year":"2020","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B92","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","article-title":"The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy","volume":"11","author":"Feng","year":"2024","journal-title":"Mil. Med Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12967-022-03827-4","article-title":"Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer","volume":"21","author":"Han","year":"2023","journal-title":"J Transl Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.038","article-title":"Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer","volume":"81","author":"Yamoah","year":"2022","journal-title":"Eur Urol."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70263-2","article-title":"A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study","volume":"13","author":"Ross","year":"2012","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.04.004","article-title":"Immune biomarkers in metastatic castration-resistant prostate cancer","volume":"5","author":"Fenor de la Maza","year":"2022","journal-title":"Eur Urol. Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3350","article-title":"Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN\/p53-deficient prostate cancer","volume":"29","author":"Chaudagar","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Rodrigues","year":"2018","journal-title":"J Clin Invest."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0355","article-title":"BiTE-ing into prostate cancer with bispecific T-cell engagers","volume":"27","author":"Kamat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Cancers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398109\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T06:31:13Z","timestamp":1732084273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1398109\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2024.1398109"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1398109","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"article-number":"1398109"}}